ClinicalTrials.gg
Not yet recruitingNCT07925190Updated Nov 9, 2026

A Phase III Study Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untreated Acute Myeloid Leukemia (AML) Patients

A Phase 3 interventional study of Mesutoclax (ICP-248) and Azacitidine (AZA) in Acute Myeloblastic Leukaemia, sponsored by Beijing InnoCare Pharma Tech Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Beijing InnoCare Pharma Tech Co., Ltd. (part of InnoCare Pharma Limited) · Phase 3, Interventional, and Treatment

Updated Nov 9, 2026Newly registeredGo to Updates ↓
Phase
Phase 3
Study type
Interventional
Enrollment
318
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

A Phase III study comparing Mesutoclax + azacitidine versus venetoclax + azacitidine in newly diagnosed acute myeloid leukemia (AML) patients

02

Conditions studied

  • Acute Myeloblastic Leukaemia
03

In context

Leukemia, Myeloid, Acute

3,667 studies on the registry are indexed under Leukemia, Myeloid, Acute; 816 are open to participants now.

This study's planned enrollment of 318 is above the median of 40 across 3,005 interventional studies indexed under Leukemia, Myeloid, Acute.

Browse Leukemia, Myeloid, Acute studies →

Lead sponsor

Beijing InnoCare Pharma Tech Co., Ltd. is the lead sponsor of 61 studies on the registry; 38 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Study participants with newly diagnosed AML (excluding acute promyelocytic leukemia [APL]) confirmed per the 2022 World Health Organization (WHO) classification criteria.
  2. Age ≥65 years; or age ≥18 years and \<65 years and ineligible for intensive chemotherapy.
  3. The participant is expected to have a survival time of at least 12 weeks.
  4. For participants aged ≥65 years: Performance Status (PS) 0-2; for participants aged ≥18 years and \<65 years: ECOG PS 0-3.
  5. Participants must have adequate hepatic and renal function.
  6. Male participants must agree to refrain from unprotected sexual intercourse and sperm donation from the first dose of product through 90 days after the last dose.
  7. Female participants must meet one of the following: ; permanently sterilized; or, for females of , have a negative serum pregnancy test within 7 days prior to the first study dose. Females of reproductive potential must agree to use one highly effective method plus a supplementary barrier contraceptive method with their partner from the date of ICF signature until 180 days after the last dose.
  8. The participant is able to communicate adequately with the investigator and comply with study procedures as specified in the protocol.
  9. The participant or their legally authorized representative voluntarily provides written .

Exclusion criteria

Exclusion Criteria:

  1. Prior antitumor treatment for myeloid hematologic .
  2. Prior history of chronic myeloid leukemia (CML), myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN).
  3. Known central nervous system (CNS) involvement of leukemia.
  4. Peripheral blood white blood cell count >25×10\^9/L prior to randomization.
  5. Active virus or virus infection.
  6. History of immunodeficiency, including positive (HIV) antibody.
  7. Use of strong or moderate /P-gp inhibitors or inducers (medications, dietary supplements, etc.) within 5 half-lives before the first dose of product.
  8. Diagnosis of another active malignant neoplasm within the past 2 years.
  9. Severe active infection requiring intravenous antimicrobial therapy.
  10. History of severe cardiovascular disease.
  11. Prior history of central nervous system disorders.
  12. History of severe bleeding diathesis.
  13. Known alcohol or substance dependence.
  14. Participants whom the investigator judges cannot adhere to the protocol due to uncontrolled medical, psychological, familial, social or geographic conditions; or participants who are unwilling or unable to follow protocol-required procedures.
  15. Pregnant or breastfeeding female participants.
  16. Malabsorption syndrome or other conditions that preclude oral administration or may interfere with drug absorption.
  17. Known to the active ingredients/ of mesutoclax tablets, venetoclax, azacitidine, or mannitol.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
318 participants (estimated)

Study arms

  • Experimental
    Mesutoclax + Azacitidine

    Drug: Mesutoclax (ICP-248) · Drug: Azacitidine (AZA)

  • Active comparator
    Venetoclax + Azacitidine

    Drug: Azacitidine (AZA) · Drug: Venetoclax

Interventions

  • DrugMesutoclax (ICP-248)

    125 mg QD, orally, until disease progression or other reasons for treatment discontinuation, whichever comes first.

  • 75 mg/m2, Day 1-7 or Day 1-5 and Day 8-9 of each Cycle, by injection

  • 400 mg QD, orally, until disease progression or other reasons for treatment discontinuation, whichever comes first.

06

What researchers measure

Primary outcomes

  1. overall survival (OS)

    Time frame: through the study completion, approximately up to 4 years

Secondary outcomes

  1. Response rates

    Rate of complete remission with negative measurable residual disease (CRMRD-), complete remission (CR) rate, and composite complete remission (CRc) rate (CRc includes CR, CR with incomplete hematologic recovery \[CRi\] , and/or CR with partial hematological recovery(CRh))

    Time frame: within 3 cycles (each cycle is 28 days) and during study treatment, approximately up to 3 years

  2. Event free survival (EFS)

    Time frame: approximately up to 3 years

  3. Duration of CR and CRc

    Duration of CR and duration of CRc

    Time frame: during study treatment period, approximately up to 3 years

  4. EFS with molecular MRD relapse

    Mesured from the date of randomization to date of treatment failure, hematological relapse, MRD relapse, or death from any cause, whichever comes first

    Time frame: approximately up to 3 years

  5. Transfusion independence rate

    Transfusion independence rate

    Time frame: approximately up to 3 years

  6. Adverse event profile per CTCAE v5.0

    Incidence, category, severity, and other characteristics of adverse events (AEs), assessed per NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0

    Time frame: from first dose to 28 days post last dose, approximately up to 3 years

  7. Numbers of Treatment cycle

    Time frame: during study treatment period, approximately up to 3 years

  8. Treatment cycle duration

    Time frame: during study treatment period, approximately up to 3 years

  9. Days of treatment per cycle

    Time frame: during study treatment period, approximately up to 3 years

  10. Patient Reported Outcomes (PRO) by European Organization for Research and Treatment of Cancer -Quality of Life Questionnaire (EORTC-QLQ-C30)

    PROs assessed by EORTC-QLQ-C30 , changes in rating compared to baseline.

    Time frame: from first dose to 28 days post last dose, approximately up to 3 years

  11. PRO by EuroQol 5-Dimension 5-Level (EQ-5D-5L)

    PROs assessed by EQ-5D-5L, changes in rating compared to baseline.

    Time frame: from first dose to 28 days post last dose, approximately up to 3 years

07

Study locations

1 site
08

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07925190
Responsible party
Sponsor
First posted
Nov 9, 2026
Start date
Nov 2026 (estimated)
Primary completion
Dec 2029 (estimated)
Completion
Jun 2030 (estimated)
Last update
Nov 9, 2026

Study contacts

Jingnan Yang
Contact
CO-Clinicaltrial@innocarepharma.com
010-66609990
Jie Jin
principal investigator · First Affiliated Hospital of Zhejiang University
Jianxiang Wang
principal investigator · Chinese Academy of Medical Sciences
Qian Jiang
principal investigator · Peking University People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion